[go: up one dir, main page]

WO2002072624A3 - Assays, methods and means for targeting streptococcal inhibitor of complement (sic) - Google Patents

Assays, methods and means for targeting streptococcal inhibitor of complement (sic) Download PDF

Info

Publication number
WO2002072624A3
WO2002072624A3 PCT/GB2002/001200 GB0201200W WO02072624A3 WO 2002072624 A3 WO2002072624 A3 WO 2002072624A3 GB 0201200 W GB0201200 W GB 0201200W WO 02072624 A3 WO02072624 A3 WO 02072624A3
Authority
WO
WIPO (PCT)
Prior art keywords
sic
complement
targeting
assays
methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/GB2002/001200
Other languages
French (fr)
Other versions
WO2002072624A2 (en
Inventor
Peter Julius Lachmann
David Jeffrey Seilly
Barbara Ann Fernie-King
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cambridge University Technical Services Ltd CUTS
Original Assignee
Cambridge University Technical Services Ltd CUTS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0106319A external-priority patent/GB0106319D0/en
Priority claimed from GB0123388A external-priority patent/GB0123388D0/en
Application filed by Cambridge University Technical Services Ltd CUTS filed Critical Cambridge University Technical Services Ltd CUTS
Priority to AU2002249342A priority Critical patent/AU2002249342A1/en
Publication of WO2002072624A2 publication Critical patent/WO2002072624A2/en
Publication of WO2002072624A3 publication Critical patent/WO2002072624A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2462—Lysozyme (3.2.1.17)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • G01N33/56944—Streptococcus

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

Streptococcal Inhibitor of Complement' (SIC) is involved in streptococcus infection, and is found to interact with and inhibit the enzymatic activity of lysozyme and to interact with secretory leucocyte proteinase inhibitor (SLPI). The interaction between the proteins and the inhibition of lysozyme and of SLPI by SIC may be disrupted, primarily in an antibiotic or therapeutic context.
PCT/GB2002/001200 2001-03-14 2002-03-14 Assays, methods and means for targeting streptococcal inhibitor of complement (sic) Ceased WO2002072624A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2002249342A AU2002249342A1 (en) 2001-03-14 2002-03-14 Assays, methods and means for targeting streptococcal inhibitor of complement (sic)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB0106319.7 2001-03-14
GB0106319A GB0106319D0 (en) 2001-03-14 2001-03-14 Assays methods and means
GB0123388.1 2001-09-28
GB0123388A GB0123388D0 (en) 2001-09-28 2001-09-28 Assays,methods and means

Publications (2)

Publication Number Publication Date
WO2002072624A2 WO2002072624A2 (en) 2002-09-19
WO2002072624A3 true WO2002072624A3 (en) 2003-04-24

Family

ID=26245827

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2002/001200 Ceased WO2002072624A2 (en) 2001-03-14 2002-03-14 Assays, methods and means for targeting streptococcal inhibitor of complement (sic)

Country Status (2)

Country Link
AU (1) AU2002249342A1 (en)
WO (1) WO2002072624A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0303809D0 (en) * 2003-02-19 2003-03-26 Hansa Medical Ab Assay
WO2018076061A1 (en) * 2016-10-26 2018-05-03 The University Of Melbourne An assay and method of treatment

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997013786A1 (en) * 1995-10-09 1997-04-17 Actinova Ltd. Streptoccal inhibitor of complement-mediated lysis, protein sic

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997013786A1 (en) * 1995-10-09 1997-04-17 Actinova Ltd. Streptoccal inhibitor of complement-mediated lysis, protein sic

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
AKESSON PER ET AL: "Protein SIC, a novel extracellular protein of Streptococcus pyogenes interfering with complement function.", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 271, no. 2, 1996, pages 1081 - 1088, XP002218452, ISSN: 0021-9258 *
FERNIE-KING B A ET AL: "STREPTOCOCCAL INHIBITOR OF COMPLEMENT INHIBITS TWO ADDITIONAL COMPONENTS OF THE MUCOSAL INNATE IMMUNE SYSTEM: SECRETORY LEUKOCYTE PROTEINASE INHIBITOR AND LYSOZYME", INFECTION AND IMMUNITY, AMERICAN SOCIETY OF MICROBIOLOGY, WASHINGTON, DC, US, vol. 70, no. 9, September 2002 (2002-09-01), pages 4908 - 4916, XP001097330, ISSN: 0019-9567 *

Also Published As

Publication number Publication date
AU2002249342A1 (en) 2002-09-24
WO2002072624A2 (en) 2002-09-19

Similar Documents

Publication Publication Date Title
WO2003088897A3 (en) Fab i inhibitors
HK1049656A1 (en) Fab i inhibitors
AU2001292757A1 (en) Modified selex processes without purified protein
AU2002366285A1 (en) Ides, an igg-degrading enzyme of streptococcus pyogenes
AU2002242633A1 (en) Fermentation process including the use of enzymes
AU2002236300A1 (en) Novel protein, gene encoding the same and method of using the same
WO2002014485A3 (en) Kallikrein gene
AU2001241674A1 (en) Variant galactose oxidase, nucleic acid encoding same, and methods of using same
WO2005033094A3 (en) Methods for the production of 3-methylamino-1-(thiene-2-yl)-propane-1-ol
WO2003004628A3 (en) Method for purifying an enzyme, a purified enzyme produced thereby, and use of this enzyme
WO2002060917A3 (en) Method to treat hemophilia
WO2004010925A3 (en) Mammalian genes involved in viral infection and tumor suppression
WO2005030131A3 (en) Bis-quinazoline compounds for the treatment of bacterial infections
AU2002216968A1 (en) Plasma fraction containing bikunin, method for the production thereof and use of the same
WO2002072624A3 (en) Assays, methods and means for targeting streptococcal inhibitor of complement (sic)
AU2002233916A1 (en) Isocitrate lyase enzyme from mycobacterium tuberculosis and inhibitory agents to combat persistent infection
AU2003239246A1 (en) Neuroprotection and cardioprotection afforded by chelators with high affinity and specificity for cations of first transition series elements
WO2003070229A3 (en) Use of proteinase inhibitors in the treatment of autoimmune diseases
WO2002094881A3 (en) Monoclonal antibody neutralising cathepsin b activity and uses thereof
WO2002031512A3 (en) Molecular interactions in hematopoietic cells
WO2001068846A3 (en) Transcription activator of the cited family
WO2001053352A3 (en) Sperm specific proteins
WO2001096381A3 (en) IMMUNIZATION OF DAIRY CATTLE WITH GapC PROTEIN AGAINST STREPTOCOCCUS INFECTION
AU2003299872A1 (en) Vmp-like sequences of pathogenic borrelia species and strains
AU2002334761A1 (en) Methods of treating drug-resistant bacterial infections

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP